In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare…

Pharmaceutical innovation is racing ahead of the US health system's ability to adjust payment models, but innovative concepts are finally emerging. We…

Below we present a list of the top 5 public biopharma companies that focus on developing RNA-based therapies. RNA interference (RNAi) is a natural…

After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the…

Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea,…

The cell and gene therapy market was valued at USD 6 billion in 2017 and is projected to exceed USD 35 billion in value by 2026. Moreover, these…

A full list of EMA ATMP approvals. Made with Visme Infographic Maker  

A full list of the cell and gene therapy products approved by the US FDA. Made with Visme Infographic Maker  

A full list of the regenerative medicine products that have been approved by the PMDA, Japan's drug regulatory body. Made with Visme…

Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the…

Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene…

Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T…